EU Okays CV Benefit Labeling for Canagliflozin in Diabetes EU Okays CV Benefit Labeling for Canagliflozin in Diabetes
The European label for the SGLT2 inhibitor canagliflozin for type 2 diabetes will now include positive cardiovascular benefit results from the CANVAS trial, while a decision from the US FDA is forthcoming.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Invokana | SGLT2 Inhibitors